The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1497
June 20, 2016
View Complete Issue         Table of Contents 2019 
Reslizumab (Cinqair) for Severe Eosinophilic Asthma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Reslizumab (Cinqair) for Severe Eosinophilic Asthma
June 20, 2016 (Issue: 1497)
The FDA has approved reslizumab (Cinqair – Teva), a humanized interleukin-5 (IL-5) antagonist monoclonal antibody, for add-on maintenance treatment of severe asthma in adults who have an eosinophilic phenotype. It is the second IL-5 antagonist...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Reslizumab (Cinqair) for Severe Eosinophilic Asthma
Article code: 1497d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.